Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 12, 2026 22:09 ET | Source: The Rosen Law Firm PA

ROSEN, A LONGSTANDING FIRM, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE

NEW YORK, Feb. 12, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ultragenyx...
February 11, 2026 11:30 ET | Source: Robbins Geller Rudman & Dowd LLP

Ultragenyx Pharmaceutical Inc. Securities Class Action Lawsuit Filed; Lead Plaintiff Deadline April 6, 2026 – RGRD Law

Ultragenyx allegedly misled investors about setrusumab’s potential Phase 3 study success in reducing fracture rates.
February 08, 2026 22:06 ET | Source: The Rosen Law Firm PA

ROSEN, NATIONALLY REGARDED INVESTOR COUNSEL, Encourages Ultragenyx Pharmaceutical Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - RARE

NEW YORK, Feb. 08, 2026 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces a class action lawsuit on behalf of purchasers of common stock of Ultragenyx...
February 05, 2026 16:57 ET | Source: Bragar Eagel & Squire

ULTRAGENYX ALERT: Bragar Eagel & Squire, P.C. Announces that a Class Action Lawsuit Has Been Filed Against Ultragenyx Pharmaceutical Inc. and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In Ultragenyx (RARE) To Contact Him Directly To Discuss Their Options If you purchased or...
February 04, 2026 19:44 ET | Source: Robbins Geller Rudman & Dowd LLP

INVESTOR ALERT: Ultragenyx Pharmaceutical Inc. (RARE) Investors with Substantial Losses Have Opportunity to Lead the Ultragenyx Class Action Lawsuit – RGRD Law

Ultragenyx allegedly misled investors about setrusumab’s potential Phase 3 study success in reducing fracture rates.
November 30, 2017 08:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx to Highlight Pipeline at Analyst and Investor Day on December 4

NOVATO, Calif., Nov. 30, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...
November 16, 2017 08:30 ET | Source: Ultragenyx Pharmaceutical Inc.

Ultragenyx Announces Completion of Patient Dosing in First Cohort of Phase 1/2 Clinical Study of DTX301 Gene Therapy in Ornithine Transcarbamylase (OTC) Deficiency

NOVATO, Calif., Nov. 16, 2017 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE), a biopharmaceutical company focused on the development of novel products for rare and ultra-rare...